Analyst Research

Report Title Price
Provider: S&P Capital IQ – STARS Reports
Provider: Stock Traders Daily
Provider: Reuters Investment Profile
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA and Transgene SA Announce New Long-Term Joint Venture for Production of Immunotherapy Treatments

Monday, 25 Mar 2013 02:00am EDT 

Sanofi SA and Transgene SA announced the collaboration agreement for the creation of a new industrial platform dedicated to the production of immunotherapy products including Transgene SA's therapeutic products. The joint venture platform will be realized on Genzyme Polyclonals site in Lyon - Gerland area for an investment amount of EUR 1.000 million equally financed by Sanofi SA and Transgene SA. The Platform will remain Sanofi SA's exclusive property. Accordingly, Sanofi SA and Genzyme are expected to act as Transgene SA's Contract Manufacturing Organization (CMO) to manufacture clinical and commercial batches of drug substance of Transgene SA's immunotherapy products, including its MVA1 therapeutic vaccines. Transgene SA will be a preferred customer of the commercial manufacturing platform for 15 years. Genzyme Polyclonals site in Lyon – Gerland area – is manufacturing polyclonal antibodies for the worldwide markets. Construction, qualification and validation of the manufacturing suite is to start in Q3 of the year 2013 and should be completed in Q1 of the year 2015. First batches of commercial grade products from the suite are expected in 2015. Transgene SA expects to file its first BLA2 in 2016. 

Company Quote

0.84 +0.98%
15 Sep 2014